|
|
 | |  | | | AUDITORIUM | 14:00 - 15:30
PHARMACOVIGILANCE AND RISK MANAGEMENT STRATEGIES |  | |  | | Leone Roberto
New and old strategies for the signal detection in pharmacovigilance |  |
| |  | |  |
| | | | Trifiro Gianluca
Role of Electronic Healthcare Database in the process of drug safety signal management | |
| | | | |
| | | | Capuano Annalisa
Post-Approval Safety Monitoring and Benefit-Risk Assessment: Post authorization safety study (PASS) | |
| | | | |
| | | | Rosano Giuseppe
The EU Pharmacovigilance Risk Assessment Committee: early year experiences |
| | | | |
| |
15:30 - 17:00
THERAPEUTIC CANNABIS | | | | | Fratta Walter
Possible role of endocannabinoid system in the physiopathology of eating disorders | |
| | | | |
| | | | Di Marzo Vincenzo
Use of cannabinoids in orphan diseases: potential for the treatment of pedriatric epilepsy and Duchenne's muscular dystrophy | |
| | | | |
| | | | Campolongo Patrizia
Are cannabinoids potential candidates for the treatment of Post-Traumatic Stress Disorder |
| | | | |
| |
17:30 - 18:30
PLENARY LECTURE | | | | | Cattaneo Elena
Huntington: from evolutionary studies to new pharmacological targets |
| | | | |
| | | | Rossi Francesco
Premiazione |
| | | | |
| |
18:30 - 19:00
SALUTI AUTORITÀ | | | | | Manfredi Gaetano
Rettore Università Federico II - Napoli |
| | | | |
| | | | Quintano Claudio
Rettore Univerità Parthenope |
| | | | |
| | | | Griesbacher Thomas
Presidente EPHAR |
| | | | |
| |
|
| |  | |  |
| | | | | AULA-MAGNA | 08:30 - 08:45
18° SEMINARIO DOTTORANDI, SPECIALIZZANDI, POST DOTTORANDI E ASSEGNISTI | | | | | Racagni Giorgio
Introduction |
| | | | |
| | | | Cirino Giuseppe
Introduction |
| | | | |
| |
08:45 - 10:00
ORAL COMMUNICATIONS - PHD STUDENTS SESSION I | | | | | Perrone Valentina
Use of oral anticoagulant therapy in the general population: a real life study after new oral anticoagulants introduction |
| | | | |
| | | | Fasolino Ines
5-Azacytidine mediated hMSC differentiation on nanofibrous sca folds for skeletal muscle regeneration |
| | | | |
| | | | Neri Laura
Stimulation of brain melanocortin MC4 receptors enhances neurogenesis and counteract cognitive decline in a transgenic mouse model of Alzheimer's disease |
| | | | |
| | | | Pellegrini Carolina
Involvement of endogenous adenosine via A2B receptors in colonic dysmotility associated with high fat diet-induced obesity |
| | | | |
| | | | Bonfanti Elisabetta
Targeting the P2Y-like receptor GPR17 to foster recovery after brain ischemia |
| | | | |
| |
10:00 - 11:15
ORAL COMMUNICATIONS - PHD STUDENTS SESSION II | | | | | Spampinato Simona
Involvement of Sphingosine 1 Phosphate receptor on the Blood Brain Barrier properties upon inflammatory stimuli? |
| | | | |
| | | | Chiazza Fausto
Role of NLRP3 inflammasome in a mouse model of diet-induced exacerbation of myocardial ischemia/reperfusion injury |
| | | | |
| | | | Gagno Sara
Role of RIZ1 delP 704 polymorphism in metastatic breast cancer patients treated with exemestane |
| | | | |
| | | | Lanzillotta Annamaria
Epigenetic drugs targeting acetylation of NF-KappaB and histones: a promising strategy to reduce post ischemic brain injury |
| | | | |
| | | | De Caro Carmen
DFL23693, a new TRPM8 antagonist, in wet-dog shake (WDS) by icilin and in a model of neuropathic pain |
| | | | |
| |
11:30 - 12:45
ORAL COMMUNICATIONS - PHD STUDENTS SESSION III | | | | | Torrisi Sebastiano Alfio
Role of central dopamine D3 and serotonin 2C receptors in the control of the mesoaccumbens dopaminergic pathway: implications for the treatment of depression |
| | | | |
| | | | Spinelli Valentina
NOS/sGC/cGK1 pathway in cardiac-specific differentiation of mouse embryonic stem cells |
| | | | |
| | | | Mantuano Paola
Cross-talk between inflammation and aberrant mechanotransduction in degenerative primary myopathies: validation of druggable targets via animal models and pharmacological studies |
| | | | |
| | | | Raschi Emanuel
Dipeptidyl peptidase-4 inhibitors (gliptins) and heart failure: data-mining of spontaneous reports submitted to the FDA Adverse Event Reporting System (FAERS) |
| | | | |
| | | | Impellizzeri Daniela
Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of inflammatory pain |
| | | | |
| |
13:00 - 13:45
PLENARY LECTURE | | | | | Racagni Giorgio
Introduction |
| | | | |
| | | | Pin Jean-Philippe
Metabotropic Glutamate Receptors: complex allosteric machines offering many possibilities for new drugs |
| | | | |
| |
14:00 - 16:00
ORAL COMMUNICATIONS - NEUROPHARMACOLOGY - SESSION I | | | | | Bedini A.
Ligand-directed signaling at kappa and mu opioid receptors: identification of novel, functionally selective ligands to develop innovative analgesic drugs |
| | | | |
| | | | Feligioni M.
Presynaptic c-Jun N-terminal Kinase 2 regulates NMDA receptor-dependent glutamate release |
| | | | |
| | | | Mango D.
Acid-sensing ion channel 1a is involved in long-term depression in the rodent hippocampus |
| | | | |
| | | | Beggiato S.
Role of Striatal A2A, D2 and mGlu5 receptor interactions in the modulation of glutamate levels from rat striatal nerve terminals |
| | | | |
| | | | Russo R.
Analgesic effects of sodium butyrate and phenylalanine-butyramide derivative in acute and chronic pain models |
| | | | |
| | | | Di Cesare Mannelli L.
Neuronal alarmin IL-1? evokes astrocyte-mediated protective signals against oxaliplatin neurotoxicity. Effectiveness in chemotherapy induced neuropathic pain |
| | | | |
| | | | De Caro C.
DFL23693, a new TRPM8 antagonist, in wet-dog shake (WDS) by icilin and in a model of neuropathic pain |
| | | | |
| | | | De Logu F.
Pyrazolone derivatives selectively inhibit TRPA1 channel in vitro |
| | | | |
| |
|
| | | | |
| | | | | MIRABILIS | 15:00 - 16:00
CLINICAL PHARMACOLOGY ASSEMBLY | | |
16:00 - 17:00
IMMUNO-ONCOLOGY: FUTURE PERSPECTIVES IN SOLID TUMOR TREATMENT | | | | | Ascierto Paolo A.
What we learned from immunotherapies in the past years |
| | | | |
| | | | Danesi Romano
The new drugs: classes and mechanisms of action |
| | | | |
| |
|
| | | | |
| | | | | PARTENOPE | 14:00 - 16:00
ORAL COMMUNICATIONS - PHARMACOLOGY OF ANTINEOPLASTIC DRUGS - SESSION I | | | | | Caderni G.
1 Prevention of colon carcinogenesis with a combination of sulindac, 3,3'-diindolylmethane and curcumin or polyethylene glycol in Apc mutated Pirc rats |
| | | | |
| | | | Panza E.
Pro-apoptotic and anti-tumoral activities of vinyl disulfides from Ferula assa-foetida L. in melanoma |
| | | | |
| | | | Sava G.
C4/3 NAMI-A controls the HCT-116 CRC invasion processes through the modulation of a5b1 integrin expression and activation |
| | | | |
| | | | Nobili S.
In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways |
| | | | |
| | | | Gervasi A.
Differential anti-tumor and cardiovascular effects of trastuzumab and T-DM1 in a xenotransplant model of NSCLC |
| | | | |
| | | | Bizzarro V.
ANXA1 is involved in the acquisition of an aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid |
| | | | |
| | | | Lisi L.
Microglia polarization in neuro-oncology |
| | | | |
| | | | Malara N. M.
A promising biomarker of early cancer detection: the liquid biopsy |
| | | | |
| |
16:00 - 17:00
ORAL COMMUNICATIONS - CLINICAL TRIALS - SESSION I | | | | | Bodini R.
A survey on support to investigator sponsored trials. Trends and proposals |
| | | | |
| | | | Smania G.
Innovative approaches to facilitate paediatric drug development |
| | | | |
| | | | Benso G.
Discovery Fast Track Challenge - Engagement in Italy. A new Pharma Academia Partnership Model to support Innovative Drug Discovery |
| | | | |
| | | | Bianco S.
Device or Not Device: challenges in the development of products containing mechanically and pharmacologically active components |
| | | | |
| |
|
| | | | |
| | | | | POSILLIPO | 14:00 - 15:00
ITAHFA-INDUSTRY ROUND TABLE | | |
15:00 - 15:50
SIF-ITAHFA JOINT SYMPOSIUM - THE CLINICAL PHARMACOLOGY OF HEART FAILURE: GENERAL ASPECTS AND SPECIAL SITUATIONS | | | | | Gensini Gian Franco
Introduction. Why ITAHFA and this Symposium |
| | | | |
| | | | Rossi Francesco
Introduction. Why ITAHFA and this Symposium |
| | | | |
| | | | Mathieu Giovanni
Heart failure: current epidemiology, clinical presentations and future perspectives |
| | | | |
| | | | Rosano Giuseppe
The comprehensive management of patients with heart failure |
| | | | |
| | | | Cerbai Elisabetta
Ion channels and transporters in heart failure |
| | | | |
| | | | Muscoli Saverio
Angiotensin and neprilysin inhibitors in heart failure: recent acquisitions |
| | | | |
| |
15:50 - 17:00
SIF-ITAHFA JOINT SYMPOSIUM - THE CLINICAL PHARMACOLOGY OF HEART FAILURE: GENERAL ASPECTS AND SPECIAL SITUATIONS | | | | | Zito Giovanni Battista
The role of the cardiologist in the territorial care process |
| | | | |
| | | | Terrazzino Salvatore
Pharmacogenetics of heart failure therapy |
| | | | |
| | | | Gronda Edoardo
Heart failure and sleep apnea |
| | | | |
| |
|
| | | | |
| | | | | SALA-A | 14:00 - 15:00
ORAL COMMUNICATIONS - PHARMACOGENETICS AND PERSONALIZED MEDICINE - SESSION I | | | | | Ravegnini G.
MicroRNA profiling in KIT and SDH mutated Gastrointestinal stromal tumor (GIST) |
| | | | |
| | | | Angelini S.
The importance of a personalized therapy in Gastrointestinal stromal tumor prognosis |
| | | | |
| | | | Gagno S.
Role of RIZ1 delP 704 polymorphism in metastatic breast cancer patients treated with exemestane |
| | | | |
| | | | Malara N. M.
CD326+ CD29+ expression in liquid and tissue biopsy to redefine personalized treatment of NSCLC |
| | | | |
| |
15:00 - 16:45
ORAL COMMUNICATIONS - INFLAMMATION PHARMACOLOGY AND IMMUNOPHARMACOLOGY - SESSION I | | | | | Mantuano P.
Cross-talk between inflammation and aberrant mechano-transduction in degenerative primary myopathies: validation of druggable targets via animal models and pharmacological studies |
| | | | |
| | | | Impellizzeri D.
Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of inflammatory pain |
| | | | |
| | | | Collino M.
Pharmacological inhibition of I?B kinase reduces the multiple organ dysfunction associated with hemorrhagic shock in the rat |
| | | | |
| | | | Paccosi S.
Inflammation and insulin-resistance affect dendritic cell function |
| | | | |
| | | | Giaroni C.
Molecular pathways involved in NO formation in myenteric neurons after in vivo ischemia/reperfusion injury in the rat small intestine |
| | | | |
| | | | Speciale A.
Cyanidin-3-O-glucoside modulates intestinal inflammatory response induced by TNF-?: an approach based on in vitro epithelial and epithelial-endothelial co-culture models |
| | | | |
| | | | Tortora T C.
Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels |
| | | | |
| |
|
| | | | |
| | | | | VESUVIO | 14:00 - 15:00
ORAL COMMUNICATIONS - DRUGS WITH EXPIRED PATENT | | | | | Ingrasciotta Y.
Short term effect on hemoglobinemia of erythropoiesis-stimulating agents in clinical practice: no difference between biosimilar and originator |
| | | | |
| | | | Guarienti M.
In silico and in vivo analysis of erythropoietin using zebrafish embryos as animal model |
| | | | |
| | | | Gianoncelli A.
A conjugate proteomic approach for the structural and functional analysis of erythropoietin alpha and its biosimilars |
| | | | |
| | | | Ingrasciotta Y.
What is the use of granulocyte colony-stimulating factors biosimilars in routine care? Results from a multicentre, population-based study from four Italian regions in the years 2009-2013 |
| | | | |
| |
15:00 - 16:45
ORAL COMMUNICATIONS - PHARMACOLOGY OF METABOLISM - SESSION I | | | | | Pellegrini C.
Involvement of endogenous adenosine via A2B receptors in colonic dysmotility associated with high fat diet-induced obesity |
| | | | |
| | | | D'Agostino G.
Nucleus of the solitary tract cholecystokinin-expressing neurons control appetite |
| | | | |
| | | | Gomaraschi M.
Plasma-derived and synthetic HDL inhibit tissue factor in endothelial cells and monocytes |
| | | | |
| | | | Zimetti F.
Effects of a new combination of berberine, monacolin k and Morus alba on lipid profile and HDL functions in healty subjects: a pilot study |
| | | | |
| | | | Favari E.
Lomitapide treatment highly affects lipoprotein profile and HDL functionality in patients with familial hypercholesterolemia |
| | | | |
| | | | Ferri N.
SOCS3 induces PCSK9 expression in hepatic HepG2 cell line |
| | | | |
| | | | Sultana J.
The management of type II diabetes in patients with chronic kidney disease: a population-based study in Southern Italy |
| | | | |
| |
|
| | | | |
| | | | | AUDITORIUM | 08:30 - 10:00
JOINT SYMPOSIUM OF BPS AND SIF - TARGETING INFLAMMATION TO REDUCE CVD RISK: A REALISTIC CLINICAL PROSPECT? WITH THE CONTRIBUTE OF EPHAR | | | | | Ahluwalia Amrita
Effects of nitrite and nitrate on the cardiovascular system in health and disease |
| | | | |
| | | | Patrono Carlo
Cardiovascular effects of nonsteroidal antiinflammatory drugs |
| | | | |
| | | | Maffia Pasquale
Is atherosclerosis a vascular or a systemic immune disease? |
| | | | |
| | | | Cirino Giuseppe
Hydrogen sulphide and cardiovascular homeostasis |
| | | | |
| |
10:00 - 10:45
PLENARY LECTURE | | |
11:00 - 13:00
SIF-AMD-ISPOR ITALY ROME CHAPTER-SIMG JOINT SYMPOSIUM - DIABETES: IMPROVEMENT OF THE CARE PATHWAYS AND EVALUATION OF DIRECT AND INDIRECT COSTS | | | | | Pisanti Paola
Diabetes national plan |
| | | | |
| | | | Medea G.
The role of general medicine in diabetes treatment | |
| | | | |
| |
14:00 - 16:00
SIF-SISA JOINT SYMPOSIUM - NEW APPROACHES IN LIPID-LOWERING THERAPY | | | | | Norata Danilo
Triglyceride rich lipoproteins and cardiovascular diseases: from genetics to pharmacology | |
| | | | |
| | | | Zambon Alberto
PCSK9 from biology to clinical practice |
| | | | |
| |
16:00 - 17:30
WHICH WILLINGNESS TO PAY? | | | | | Mennini Francesco Saverio
Presentation "Allocation of resources and willingness to pay" ? System sustainability ? Willingness to pay ? New virtuous models for the best allocation of resources |
| | | | |
| | | | Scrivo Roberto
Round table: ideas, suggestions, additions |
| | | | |
| | | | Pisanti Paola
Round table: ideas, suggestions, additions |
| | | | |
| | | | Riccini Carlo
Round table: ideas, suggestions, additions |
| | | | |
| |
|
| | | | |
| | | | | AULA-MAGNA | 11:00 - 11:30
HORIZON SCANNING OF MYELOMA AND LYMPHOMA - THE ONCOLOGICAL PHARMACOLOGY GROUP EXPERIENCE | | | | | Minotti Giorgio
Introduction |
| | | | |
| | | | Danesi Romano
Horizon scanning of myeloma and lymphoma -The Oncological Pharmacology Group experience |
| | | | |
| |
11:30 - 12:00
POSITION PAPERS ON BIOSIMILARS | | | | | Genazzani Armando
Position papers on biosimilars |
| | | | |
| |
12:00 - 12:30
OXIDATIVE STRESS AND EXACERBATION OF COPD: ROLE OF NAC | | | | | Caputi Achille Patrizio
Introduction |
| | | | |
| | | | Cazzola Mario
Oxidative stress and exacerbation of COPD: role of NAC |
| | | | |
| |
12:30 - 13:00
ADVANCED NSCLC: 10 YEARS OF CHANGES | | | | | Novello Silvia
Advanced NSCLC: 10 years of changes |
| | | | |
| |
14:00 - 15:00
SIF-SIE JOINT SYMPOSIUM - T-CELL ENGAGEMENT STRATEGIES: A NEW ERA FOR ALL | | | | | Danesi Romano
Mechanism of action of T-cell engagement treatments |
| | | | |
| | | | Locatelli Franco
The place of antibody-mediated immunotherapy in the treatment of childhood ALL |
| | | | |
| | | | Rambaldi Alessandro
Modern therapy of Acute Lymphoblastic Leukemia in adult patients |
| | | | |
| |
15:00 - 16:00
SIF-SIE JOINT SYMPOSIUM - INNOVATION IN PHARMACOLOGICAL TREATMENT IN ONCOHEMATOLOGY | | | | | Danesi Romano
Pharmacological resistance in hematologic malignancies |
| | | | |
| | | | Massaia Massimo
Novel drugs in chronic lymphocytic leukemia |
| | | | |
| | | | Giuliani Nicola
New drugs in the treatment of multiple myeloma: proteasome inhibitors and monoclonal antibodies |
| | | | |
| |
16:00 - 17:30
INDUSTRY-ACADEMIA PARTNERSHIPS: ARE WE READY TO MEET? | | | | | Granieri Massimiliano
Technology transfer as a tool to potentiate basic science |
| | | | |
| | | | Recchia Giuseppe
New approaches to develop industry-academia partnerships in Italy |
| | | | |
| | | | Tongiani Serena
Critical issues when attempting to create partnerships with academia |
| | | | |
| | | | Chiesi Andrea
What are industries looking for? What should academia be doing? |
| | | | |
| |
17:30 - 19:00
OLD AND NEW DRUGS IN THE MODULATION OF REWARD AND EMOTIONAL BEHAVIOUR | | | | | Luoni Alessia
Stress-induced synaptic changes: modulation by lurasidone treatment |
| | | | |
| | | | Campolongo Patrizia
Role of the endocannabinoid system in the modulation of memory for traumatic experiences |
| | | | |
| | | | Trezza Viviana
Cannabinoid modulation of socio-emotional behavior |
| | | | |
| | | | Fattore Liana
The novel psychoactive substance methoxetamine (MXE) affects brain reward and emotional processing in rats |
| | | | |
| |
|
| | | | |
| | | | | MIRABILIS | 08:30 - 10:00
SIF-ITALIAN PURINE CLUB JOINT SYMPOSIUM THE PURINERGIC SYSTEM AS A NEW, PROMISING TARGET TO TREAT HUMAN DISEASES | | | | | Cronstein Bruce
Targeting Adenosine Receptors in Health and Disease |
| | | | |
| | | | Abbracchio Maria Pia
The purinergic system as a target for demielinating diseases |
| | | | |
| | | | Coppi Elisabetta
Role of P1 and P2 purinergic receptors during severe in vitro ischemia in the rat CA1 hippocampus and dentate gyrus |
| | | | |
| | | | Popoli Patrizia
Adenosine A2A receptors as a target to treat Niemann - Pick C disease |
| | | | |
| | | | Morelli Micaela
Antidyskinetic activity of adenosine A2A and 5-HT1A/1B receptor targeting in models of Parkinson's disease: acute and chronic studies |
| | | | |
| |
12:00 - 13:00
SIF-SIN JOINT SYMPOSIUM - MULTIPLE SCLEROSIS: STATE OF THE ART AND FUTURE PERSPECTIVES - THIS EVENT WAS MADE POSSIBILE THANKS TO AN UNCONDITIONAL GRANT BY BIOGEN | | | | | Tedeschi Gioacchino
Multiple Sclerosis |
| | | | |
| | | | Maione Sabatino
Round table: therapeutic value and sustainability of new MS treatments |
| | | | |
| | | | Lugaresi Alessandra
Round table: therapeutic value and sustainability of new MS treatments |
| | | | |
| | | | Mantovani Lorenzo
Round table: therapeutic value and sustainability of new MS treatments |
| | | | |
| |
14:00 - 15:00
THE NEUROIMMUNE PHARMACOLOGY OF MULTIPLE SCLEROSIS - THIS EVENT WAS SPONSORED BY ROCHE | | | | | Nicoletti Ferdinando
Neuroinflammation and Neurodegeneration in MS |
| | | | |
| | | | Comi Giancarlo
Targeting B-cell in MS treatment |
| | | | |
| |
15:00 - 15:30
UNMET NEEDS IN PARKINSON DISEASE: THE ROLE OF SAFINAMIDE | | | | | Canonico Pier Luigi
Introduction |
| | | | |
| | | | Fariello Ruggero
Unmet needs in Parkinson disease: the role of safinamide |
| | | | |
| |
15:30 - 17:30
THE ROLE OF ADHERENCE IN THE SUCCESS OF PHARMACOLOGICAL TREATMENT - THIS EVENT WAS MADE POSSIBILE THANKS TO A GRANT BY PFIZER | | | | | Di Minno Giovanni
Ensuring medication adherence with direct oral anticoagulant drugs. Lessons from adherence with vitamin K antagonists (VKAs) |
| | | | |
| | | | Perrone Pasquale
Improving adherence in clinical practice: from blood pressure control to cardiovascular events reduction |
| | | | |
| | | | Marchettini Paolo
Evidence and experience based neuropathic pain treatment |
| | | | |
| | | | Favalli Ennio
The importance of adherence in patients with inflammatory rheumatic diseases |
| | | | |
| | | | Danesi Romano
The role of adherence in oncology |
| | | | |
| |
17:30 - 19:00
SIF-SSFA JOINT SYMPOSIUM - RESEARCH AND DEVELOPMENT OF ORPHAN DRUGS | | | | | Criscuolo Domenico
The role of the pharmaceutical industry in orphan drugs development |
| | | | |
| | | | Desaphy Jean-Francois
Hereditary ion channelopathies: from gene to disease to precision medicine |
| | | | |
| | | | Fornasari Diego
Therapeutic approaches to Ondine's syndrome |
| | | | |
| | | | Graziano Ermelinda
Challenges in the development of an orphan drug |
| | | | |
| |
|
| | | | |
| | | | | PARTENOPE | 08:30 - 10:00
SARCOPENIA: FROM PATHOPHYSIOLOGY TO EXPERIMENTAL STUDIES TO DEFINE EFFECTIVE PHARMACOLOGICAL APPROACHES | | | | | Rosano Giuseppe
Sarcopenia: epidemiology and current treatments |
| | | | |
| | | | Tricarico Domenico
Functional properties of the sarcopenic muscle and pharmacological approaches |
| | | | |
| | | | Raimondi Laura
Drug targets in resident satellite cells |
| | | | |
| | | | Sartiani Laura
The RAS system in self-renewal and differentiation of satellite cells |
| | | | |
| |
11:00 - 12:00
RETINAL DISEASES: THE APPROPRIATE GOVERNANCE CHALLENGES | | | | | Mastropasqua Leonardo
High-tech in retinal disease management |
| | | | |
| | | | Sportiello Liberata
Role of anti-VEGF in retinal diseases |
| | | | |
| | | | Russo Alessandra
The use of intravitreal steroid inplant for the treatment of retinal diseases: efficacy and safety |
| | | | |
| |
12:00 - 13:00
SIF-SITECS JOINT SYMPOSIUM - COMBINATION THERAPY IN CONTROLLING HYPERCHOLESTEROLEMIA AND CARDIOVASCULAR PREVENTION | | | | | Poli Andrea
The lower, the better: recent evidences |
| | | | |
| | | | Corsini Alberto
Ezetimibe and LDL: a unique mechanism of action |
| | | | |
| | | | De Ferrari Gaetano
How should we apply the finding of the IMPROVE-IT study in our clinical practice? |
| | | | |
| |
14:00 - 16:00
SIF-FADOI JOINT SYMPOSIUM - THE VIRTUOUS CIRCLE PHARMACOLOGY-CLINICS: NEW PERSPECTIVES FOR THE TREATMENT OF HEART FAILURE | | | | | Fontanella Andrea
Heart failure and comorbidities |
| | | | |
| | | | Vescovo Giorgio
Unmet clinical needs in the pharmacological treatment of heart failure |
| | | | |
| | | | Mollace Vincenzo
New drugs for heart failure |
| | | | |
| | | | Mantovani Lorenzo
The cost of heart failure |
| | | | |
| |
16:00 - 17:00
IL-17-MEDIATED INFLAMMATION AND ITS CLINICAL SIGNS | | | | | Riccardi Carlo
IL-17 pharmacology |
| | | | |
| | | | Rossini Maurizio
Bone involvement in inflammatory arthritis: the role of IL-17 |
| | | | |
| | | | Girolomoni Giampiero
Psoriasis: clinical aspects and therapeutic targets |
| | | | |
| |
17:00 - 19:00
DRUGS IN PRIMARY CARE | | | | | Garattini Silvio
How to improve appropriateness in the use of drugs |
| | | | |
| | | | Martini Nello
A new pharmaceutical governance in the Primary Care reform |
| | | | |
| | | | Raschetti Roberto
Evidence, uncertainty and medical pratice |
| | | | |
| | | | Giustini Saffi Ettore
Some considerations about OSMED 2014 |
| | | | |
| |
|
| | | | |
| | | | | POSILLIPO | 08:30 - 10:00
TRP CHANNELS AND OTHER TARGETS | | | | | Di Marzo Vincenzo
Hitting thermo-TRPs and other targets: a more efficacious and safer strategy to treat pain? |
| | | | |
| | | | Nassini Romina
TRPA1 in neuropathic and migraine pain |
| | | | |
| | | | Lattanzi Roberta
Bv8/Prokineticin in pain transmission |
| | | | |
| |
11:00 - 12:30
FROM THE PAST TO THE FUTURE OF NUTRACEUTICALS | | | | | Novellino Ettore
From the past to the future of Nutraceuticals |
| | | | |
| | | | Stiuso Paola
The nutraceuticals in the treatment and prevention of chronic diseases: recent acquisition by biochemical research |
| | | | |
| | | | Ritieni Alberto
The safety of the nutraceuticals and their sources |
| | | | |
| |
12:30 - 13:00
KNOWLEDGE DRIVEN PHARMACOTHERAPY IN NEONATES IS FEASIBLE AND NEEDED | | | | | Mugelli Alessandro
Introduction |
| | | | |
| | | | Allegaert Karel
Knowledge driven pharmacotherapy in neonates is feasible and needed |
| | | | |
| |
14:00 - 16:00
NEW DRUGS FOR TYPE 2 DIABETES AND OBESITY TREATMENT | | | | | Nicolucci Antonio
Diabetes, overweight and obesity: epidemiology and socioeconomic burden |
| | | | |
| | | | Sturis Jeppe
Innovation in the pharmacological research |
| | | | |
| | | | Sesti Giorgio
New Treatment for type 2 diabetes: beyond glycemic control - Insulin Therapy |
| | | | |
| | | | Sbraccia Paolo
Central effects of GLP-1 Receptor Agonists |
| | | | |
| |
16:00 - 17:30
ORAL COMMUNICATIONS - DRUGS OF ABUSE | | | | | Caputi F. F.
The ubiquitination machinery as a new target of cocaine and ethanol effects: gene expression and activity alterations of the 26S proteasome in neuroblastoma cells |
| | | | |
| | | | Grassi M. C.
Association between positivity, happiness and smoking cessation |
| | | | |
| | | | Scuppa G.
Nociceptin receptor (NOP) knock out rats show a reduced propensity to self-administer drugs of abuse |
| | | | |
| | | | Zanotti I.
Differential effects of moderate and excess alcohol consumption on the atheroprotective process of the reverse cholesterol transport in vivo |
| | | | |
| | | | Brancato A.
Perinatal alcohol intake, maternal behaviour and transgenerational inheritance of drug abuse; effects of drinking pattern and environmental enrichment |
| | | | |
| | | | Fogli S.
Clinical validation of a mass spectrometer-based method for measuring nicotine-metabolite ratio to optimize smoking cessation pharmacotherapies |
| | | | |
| |
17:30 - 19:00
SIF-SINDEM - JOINT SYMPOSIUM - ALZHEIMER'S DISEASE AND ANTI-AMYLOID ß IMMUNOTHERAPY CLINICAL STUDIES. A CRITICAL REVIEW | | | | | Marcello Elena
Has the amyloid cascade a central role in Alzheimer's disease pathogenesis? |
| | | | |
| | | | Padovani Alessandro
Two perspectives on anti-amyloid ß immunotherapy clinical studies for Alzheimer's disease - Limits in the design and interpretation of controlled clinical trials based on anti-amyloid agents |
| | | | |
| | | | Musicco Massimo
Two perspectives on anti-amyloid ß immunotherapy clinical studies for Alzheimer's disease - Limits of the amyloid cascade hypothesis in the pathogenesis of Alzheimer's disease, lessons from randomized controlled trials |
| | | | |
| | | | Dell'Agnello Grazia
What is the future of the anti-amyloid treatments for Alzheimer's disease. The pharmaceutical companies' opinion |
| | | | |
| |
|
| | | | |
| | | | | SALA-A | 11:00 - 13:00
ORAL COMMUNICATIONS - PHARMACOEPIDEMIOLOGY - SESSION I | | | | | Roberto G.
Identifying cases of type 2 diabetes from heterogeneous data sources: strategy from the EMIF Project |
| | | | |
| | | | Pirolo R.
Lights and shadows in the anti-diabetic therapy |
| | | | |
| | | | Ferrara R.
Can a clinical educational program improve the management of chronic obstructive pulmonary disease (COPD)? Results from a prospective cohort study in the Sicilian general practice setting |
| | | | |
| | | | Santini G.
Breathomics distinguishes between anti-IgE-treated and non-treated adults with severe asthma |
| | | | |
| | | | Piccinni C.
Exposure to potentially teratogenic drugs in pregnancy and perinatal outcomes: observational study on deliveries occurred in Emilia Romagna region between 2009 and 2011 |
| | | | |
| | | | Italiano D.
Gabapentin and pregabalin use in general practice: evaluation of use and appropriateness during the years 2005 - 2011 |
| | | | |
| | | | Tarozzi A.
Quality of life and drug use: a gender analysis |
| | | | |
| | | | Poluzzi E.
Experience with generic medicines in Italy: a questionnaire?based survey of prescribers, pharmacists and patients |
| | | | |
| |
14:00 - 15:45
ORAL COMMUNICATIONS - CLINICAL TRIALS - SESSION II | | | | | Arpinelli F.
Randomized clinical trials and observational studies: which data from which studies in respiratory field? |
| | | | |
| | | | Vincenzi F.
Role of A2A adenosine receptors in multiple sclerosis patients |
| | | | |
| | | | Mattioli F.
Meropenem population pharmacokinetics in patients affected by arbapenemase-producing K. pneumonie |
| | | | |
| | | | Gussoni G.
The quality of drug prescription for elderly patients in medical wards. A randomized controlled study to evaluate the effects of an e-learning educational program in elderly patients hospitalized in Internal Medicine and Geriatric wards |
| | | | |
| | | | Bianco S.
Sugar and spice: specificities of clinical evaluation of food supplements and herbal products |
| | | | |
| | | | Rizzi A.
Towards a new model of scientific interaction between Pharma and HCP: the Global HCP Engagement Initiative |
| | | | |
| |
15:45 - 17:15
ORAL COMMUNICATIONS - PHARMACOGENETICS AND PERSONALIZED MEDICINE - SESSION II | | | | | Bernardi F. F.
The combination of pharmacogenetic and pharmacokinetic analyses to optimise clomipiramine dosing: a case report |
| | | | |
| | | | Squassina A.
A genome wide microRNA investigation suggests new biomarkers in suicide and lithium targets |
| | | | |
| | | | Stocco G.
Pharmacogenetic determinants of response to infliximab in pediatric inflammatory bowel disease |
| | | | |
| | | | Farinato A.
Pharmacological characterization of a hNav1.4 sodium channel mutation causing paramyotonia congenita |
| | | | |
| | | | Cojutti P. G.
Personalization of linezolid dosing regimen at a tertiary-care hospital setting: how much does it impact on drug exposure and therapy costs? |
| | | | |
| | | | Falvella F. S.
Risk of thromboembolic events in metastatic colorectal cancer patients with single nucleotide polymorphisms in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR) |
| | | | |
| |
17:15 - 19:00
ORAL COMMUNICATIONS PHARMACOVIGILANCE - SESSION I | | | | | Gussoni G.
Drug therapy and other risk factors for hypoglycemia in patients with type 2 diabetes, hospitalized in Internal Medicine wards. Findings from the FADOI-DIAMOND Study |
| | | | |
| | | | Convertino I.
Bleeding related to oral anticoagulant drugs as cause of emergency department admission: analysis of data from the Tuscan MEREAFaPS Network |
| | | | |
| | | | Sullo M. G.
Gastrointestinal complications and use of NSAIDs, low-dose aspirin and combination of them: results of spontaneous reporting from a Southern Italian area |
| | | | |
| | | | Mascolo A.
Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of postmarketing surveillance |
| | | | |
| | | | Licata S.
Estimated AUC of mycophenolate mofetil in pediatric patients with hematopoietic cell translaptation using a reduced sampling model validated for kidney transplant |
| | | | |
| | | | Ferrajolo C.
Use of asthma drugs and risk of hepatotoxicity in children: a population-based, case-control study |
| | | | |
| | | | Pizzimenti V.
Hypoglycaemia with antidiabetic drugs: results from a prospective pharmacovigilance study in Sicily |
| | | | |
| |
|
| | | | |
| | | | | SANTA-LUCIA | 13:00 - 14:00
BIOGEN PIPELINE LUNCH - BIOGEN COMMITMENT IN NEURODEGENERATIVE DISORDERS | | | | | Banfi Giuseppe
Introduction |
| | | | |
| | | | Paes Dominic
Biogen commitment in neurology research |
| | | | |
| |
|
| | | | |
| | | | | VESUVIO | 11:00 - 12:45
ORAL COMMUNICATIONS - CARDIOVASCULAR PHARMACOLOGY - SESSION I | | | | | Giuliani D.
Melanocortins protect rats undergoing cardiac arrest |
| | | | |
| | | | Calderone V.
Kv7.4 channels in rat cardiac mitochondria: new targets for cardioprotection |
| | | | |
| | | | Madeddu D.
Differential response to beta blockers of human endothelial cells from different sources |
| | | | |
| | | | Brancaleone V.
Hydrogen sulfide biosynthesis is blocked by D-penicillamine action on cystathionine-?-lyase |
| | | | |
| | | | Mitidieri E.
Impairment of EDHF/H2S pathway in early state of glucocorticoid induced hypertension in rat |
| | | | |
| | | | Vellecco V.
Gliptins modulate vascular tone through L-arginine/eNOS Pathway |
| | | | |
| | | | Raschi E.
Dipeptidyl peptidase-4 inhibitors (gliptins) and heart failure: data mining of spontaneous reports submitted to the FDA Adverse Event Reporting System (FAERS) |
| | | | |
| |
14:00 - 15:00
SIF -FIMMG - JOINT SYMPOSIUM DRUGS WITH EXPIRED PATENT | | | | | Falasco Cinzia
Generic drugs: status of the art and open issues |
| | | | |
| | | | Marrocco Walter
Legislation and clinical practice: lights and shadows |
| | | | |
| | | | Sottosanti Laura
Pharmacovigilance issues related to generic drugs and biosimilars |
| | | | |
| |
15:00 - 16:00
PHOSPHODIESTERASE 4 MODULATION IN IMMUNE-MEDIATED DISEASES | | | | | Fornasari Diego
PDE4 modulation in immune-mediated diseases |
| | | | |
| | | | Cauli Alberto
Clinical development of PDE4 inhibitors: rheumatologist's point of view |
| | | | |
| | | | Costanzo Antonio
Clinical development of PDE4 inhibitors: dermatologist's point of view |
| | | | |
| |
16:00 - 17:30
PATHOPHYSIOLOGY AND PHARMACOLOGY OF FPR2 RECEPTOR AND ITS LIGANDS | | | | | Perretti Mauro
Resolution Pharmacology: harnessing FPR2 biology |
| | | | |
| | | | D'Acquisto Fulvio
Formyl peptide receptor pathway as novel target for emotional disorders |
| | | | |
| | | | Rossi Settimio
Role of FPR2 receptor in uveitis |
| | | | |
| |
17:30 - 19:00
SIF-SIR JOINT SYMPOSIUM - ADVANCES IN RETINAL PHARMACOLOGY AND CLINICAL PERSPECTIVES | | | | | Bonini Stefano
Introduction |
| | | | |
| | | | Simonelli Francesca
Gene Therapy for Retinal Dystrophies: current and future perspectives |
| | | | |
| | | | Staurenghi Giovanni
Classical therapeutic approach (steroids) |
| | | | |
| | | | Scaglione Francesco
Novel therapeutic approaches in retinopathy treatment: the point of view of the pharmacologist |
| | | | |
| | | | Midena Edoardo
Innovative therapeutic approaches in the treatment of retinal disorders: the retinologist perspective |
| | | | |
| |
|
| | | | |
| | | | | AUDITORIUM | 08:30 - 10:00
NEW PHARMACOLOGICAL APPROACHES IN THE MANAGEMENT OF INFLAMMATORY PROCESSES | | | | | Esposito Emanuela
Regulatory role of PPARs in neuroinflammation and their underlying mechanisms for neuroprotective effects | |
| | | | |
| | | | Travelli Cristina
Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors: anti-cancer agents and modulators of cancer-related inflammation | |
| | | | |
| | | | Bruscoli Stefano
Role of GILZ in mediating the anti-inflammatory actions of glucocorticoids | |
| | | | |
| | | | Luongo Livio
Emerging targets on non neuronal cells and new phenotypes of microglia in chronic neuroinflammatory diseases | |
| | | | |
| |
10:00 - 10:45
PLENARY LECTURE | | |
11:00 - 13:00
ROUND TABLE "NEW HORIZONS IN PHARMACOLOGICAL RESEARCH: BETWEEN ETHICS AND SCIENCE" | | |
14:00 - 16:00
THE STATE OF CLINICAL RESEARCH: CRITICALITIES AND FUTURE PERSPECTIVES | | | | | Petraglia Sandra
The Italian clinical research scenario: criticalities and future perspectives |
| | | | |
| | | | Agnelli Giancarlo
The value of clinical research as relaunch channel of R&D activities in our Country | |
| | | | |
| | | | Ricciardi Walter
The research infrastructure contribution to the national and international Research System | |
| | | | |
| | | | Scatigna Marco
The value of clinical research as an instrument for competitiveness relaunch of our Country | |
| | | | |
| | | | Patrono Carlo
Independent clinical research. What is the future? |
| | | | |
| | | | Agostini Maurizio
Activities and synergies to face the challenges of European regulation |
| | | | |
| |
16:00 - 18:00
SIF-SIIA JOINT SYMPOSIUM - THERAPEUTIC APPROPRIATENESS IN HYPERTENSIVE PATIENT | | | | | Rossi Francesco
Importance of the renin-angiotensin system and its modulating drugs |
| | | | |
| | | | Parretti Damiano
Antihypertensive drugs are not all the same: right drug to right patient | |
| | | | |
| |
18:00 - 20:00
GENERAL ASSEMBLY OF THE SOCIETY - LIFETIME ACHIEVEMENT AWARD | | |
|
| | | | |
| | | | | AULA-MAGNA | 08:30 - 10:00
CIRCULATING EXTRACELLULAR VESICLES: CELLULAR MEDIATORS, BIOMARKERS AND THERAPEUTIC TOOLS | | | | | Perretti Mauro
Tissue-protective properties of neutrophil microvesicles in inflammatory diseases |
| | | | |
| | | | Cappello Francesco
Hsp60 levels in circulating exosomes in patients affected by large bowel cancer before and after ablative surgery |
| | | | |
| | | | Benussi Luisa
Extracellular vesicles in the pathogenesis of Alzheimer's disease and related disorders |
| | | | |
| | | | Camera Marina
Extracellular vesicles as biomarkers in coronary artery diseases |
| | | | |
| |
14:00 - 16:00
SIF-AIOM JOINT SYMPOSIUM - HOW TO MAINTAIN THE LONG-TERM SUSTAINABILITY OF PHARMACEUTICAL INNOVATION: NEW DRUGS AND NEW ENDPOINTS IN ONCOLOGY - THIS EVENT WAS SPONSORED BY ROCHE | | | | | Gentile Alfonso
Onco-hematology pipeline: an overview |
| | | | |
| | | | Jommi Claudio
Sustainability and innovation |
| | | | |
| | | | Ciardiello Fortunato
From clinical trial to clinical practice |
| | | | |
| | | | Perrone Francesco
Actual clinical endpoints and new scenarios |
| | | | |
| |
16:00 - 17:00
SIF-AIOM JOINT SYMPOSIUM - ONCOLOGY AT A CROSSROAD: THE USE OF BIOMARKERS IN TARGET THERAPY | | | | | Pensabene Matilde
Biomarkers in clinical practice, in the era of target therapy. Innovative therapies for metastatic carcinomas patients Personalized therapy in ovarian carcinoma |
| | | | |
| | | | Novello Silvia
Focus on lung cancer EGFR mutated patients: beyond first line |
| | | | |
| | | | Clementi Emilio
Preventing adverse drug reactions: the role of clinical pharmacology and pharmacogenetics |
| | | | |
| |
17:00 - 18:00
SIF-AIOM JOINT SYMPOSIUM - ROUND TABLE. QUALITY OF LIFE: THE CLINICAL PHARMACOLOGY CONTRIBUTION FROM CLINICAL TRIALS TO CLINICAL PRACTICE | | | | | Clementi Emilio
Quality of life: the clinical pharmacology contribution from clinical trials to clinical practice |
| | | | |
| | | | Mancuso Annamaria
Quality of life: the clinical pharmacology contribution from clinical trials to clinical practice |
| | | | |
| | | | Novello Silvia
Quality of life: the clinical pharmacology contribution from clinical trials to clinical practice |
| | | | |
| | | | Lauria Rossella
Quality of life: the clinical pharmacology contribution from clinical trials to clinical practice |
| | | | |
| |
|
| | | | |
| | | | | MIRABILIS-A | 08:30 - 10:00
NEW RECENT ADVANCES ON GLUTAMATE RECEPTORS AND THEIR ROLE IN CNS | | | | | Pittaluga Anna Maria
Metamodulation of NMDA receptors in central nervous system |
| | | | |
| | | | Gardoni Fabrizio
Synapse-to-nucleus signalling and activation of synaptic NMDA receptors: role in neurodegenerative diseases |
| | | | |
| | | | Usiello Alessandro
D-aspartate: an endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia |
| | | | |
| | | | Pellegrini-Giampietro Domenico
Differential role of ionotropic and metabotropic glutamate receptors in immature and mature hippocampal slices exposed to ethanol dependence and withdrawal |
| | | | |
| | | | Nicoletti F.
Epigenetic down-regulation of type-2 metabotropic glutamate receptors is linked to selective neuronal vulnerability following global transient brain ischemia |
| | | | |
| |
14:00 - 16:00
HCV HOT TOPICS: CLINICAL BENEFITS AND FINANCIAL IMPACT IN ITALY | | | | | Craxi Antonio
Innovation in HCV treatment |
| | | | |
| | | | Bruno Raffaele
The right tratment for HCV and co-infected patients |
| | | | |
| | | | Pani Luca
The challenge in price negotiation |
| | | | |
| | | | Gasbarrini Antonio
Hepatitis national plan at the experts test-stand |
| | | | |
| | | | Bruno Raffaele
Round table: eradication target |
| | | | |
| | | | Craxi Antonio
Round table: eradication target |
| | | | |
| | | | Gasbarrini Antonio
Round table: eradication target |
| | | | |
| | | | Russo P.
Round table: eradication target |
| | | | |
| |
16:00 - 16:30
EVOLUTION OF RESISTANCE OLD AND NEW ANTIBIOTICS | | |
16:30 - 18:00
UNDERSTANDING NEW MOLECULAR PATHWAYS IN THE PATHOGENESIS OF NEUROPSYCHIATRIC DISORDERS: ANIMAL MODELS TOWARDS TRANSLATIONAL APPROACHES | | | | | Govoni Stefano
Rats, mice and dementia: a classical neurochemical approach |
| | | | |
| | | | Esposito Giuseppe
Enteric glia regulates HIV - tat - induced diarrhea and cognitive dysfunction through gut-brain axis connection |
| | | | |
| | | | Schiavone Stefania
Redox dysregulation in psychiatric disorders: new biomarkers in animal models and human pathology |
| | | | |
| | | | Caraci Filippo
Impairment of neurotrophin signaling in Alzheimer's disease: searching for new pharmacological targets |
| | | | |
| |
|
| | | | |
| | | | | MIRABILIS-B | 08:30 - 10:00
NICOTINE AND NICOTINIC RECEPTORS: NEW ADVANCES IN PHYSIOLOGY AND PHARMACOLOGY | | | | | Gotti Cecilia
Regulation of nicotinic receptor subtypes by nicotine: in vivo studies |
| | | | |
| | | | Marchi Mario
Nicotinic modulation of glutamate receptor function at nerve terminal level: a fine tuning of synaptic signals |
| | | | |
| | | | Sala Mariaelvina
Electronic cigarette-induced dependence: short and long term effects |
| | | | |
| | | | Collo Ginetta
Nicotine produces structural plasticity in dopaminergic neurons: evidence from mouse neuronal cultures and human IPSC-derived neurons |
| | | | |
| | | | Pistis Marco
Regulation of nicotinic receptors by PPAR?: therapeutic perspectives |
| | | | |
| |
14:00 - 15:00
PUFA N-3: EVIDENCES IN CARDIOVASCULAR PREVENTION | | | | | Volpe Roberto
PUFA n-3: food, supplement, drug |
| | | | |
| | | | Minghetti Paola
Medicinal products or health foods: which are the different requirements |
| | | | |
| | | | Navarra Pierluigi
A rocky path to the development of generic drugs |
| | | | |
| |
15:00 - 16:15
THE IMPACT OF REGIONAL REGULATORY MEASURES ON BIOSIMILAR AND EQUIVALENT DRUGS ADVERSE REACTIONS REPORTS | | | | | Leone Roberto
Impact of regulatory regional measures on Italian reporting of adverse drug reactions to biosimilar and bioequivalent drugs: an interregional research project promoted by SIF and Assogenerici |
| | | | |
| | | | Capuano Annalisa
Pharmacovigilance of biosimilar drugs |
| | | | |
| | | | Radice Sonia
Pharmacovigilance of biosimilar drugs in frail populations |
| | | | |
| | | | Cutroneo Paola M.
The effect of Sicilian Regional health policy interventions on adverse drug reaction (ADR) reportings to biosimilar and bioequivalent drugs |
| | | | |
| |
16:30 - 18:00
FOOD FOT THOUGHT: WHEN UNBALANCED DIETS LEAD TO UNBALANCED BRAILS | | |
|
| | | | |
| | | | | PARTENOPE | 08:30 - 10:00
NEUROPSYCHOPHARMACOLOGICAL RESEARCH TODAY: GREAT EFFORTS, FEW CANDIDATES, FREQUENT FAILURES | | | | | Biggio Giovanni
The new frontiers of neurobiology and development of new drugs |
| | | | |
| | | | Spalletta Gianfranco
Neuropsychopharmacology of neuropsychiatric phenomena in neurodegenerative disorders: critical points and future directions |
| | | | |
| | | | Steardo Luca
Targeting glial cells to develop novel therapeutics in neuropsychiatry |
| | | | |
| |
14:00 - 15:00
NEW PERSPECTIVES ON IMMUNOINFLAMMATORY DISEASES | | | | | Cuzzocrea Salvatore
Mechanism of action of novel small molecules in immunoinflammatory disease, with focus on clinical data |
| | | | |
| | | | Costanzo Antonio
Clinical benefits for dermatological disease |
| | | | |
| | | | Scarpa Raffaele
Novel therapeutic targets in the treatment of psoriasis and psoriatic arthritis |
| | | | |
| |
15:00 - 15:30
INHALED BRONCHODILATORS IN COPD PATIENTS: OPTIMIZING SINERGY | | | | | Matera Maria Gabriella
Inhaled bronchodilators in COPD patients: optimizing sinergy |
| | | | |
| |
15:30 - 16:00
NEW THERAPIES FOR THE TREATMENT OF PULMONARY HYPERTENSION | | | | | Vizza Dario C.
New therapies for the treatment of pulmonary hypertension |
| | | | |
| |
16:00 - 16:30
NEW EVIDENCES IN NEUROUMORAL MODULATION IN PATIENTS WITH HEART FAILURE: THE CLINICAL TRIALS ON ANGIOTENSIN AND NEPRILYSIN RECEPTORS | | | | | Mollace Vincenzo
Introduction |
| | | | |
| | | | Volterrani Maurizio
New evidences in neuroumoral modulation in patients with heart failure: the clinical trials on angiotensin and neprilysin receptors |
| | | | |
| |
16:30 - 18:00
THERAPEUTICS IN SPINAL AND CENTRAL PROCESSING OF PAIN AND ANALGESIA | | | | | Maione Sabatino
Glutamate receptors in chronic pain-induced neuroplasticity |
| | | | |
| | | | Di Cesare Mannelli Lorenzo
Involvement of nicotinic receptor subtypes in neuropathic pain |
| | | | |
| | | | Sacerdote Paola
Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain |
| | | | |
| |
|
| | | | |
| | | | | POSILLIPO | 08:30 - 10:00
ESTROGENS AND PATHOLOGIES ASSOCIATED WITH AGEING | | | | | Della Torre Sara
Energy metabolism and fertility as an essential balance for healthy in women |
| | | | |
| | | | Eva Carola
Sex-dependent vulnerability to neurological disorders |
| | | | |
| | | | Ciana Paolo
Molecular imaging to study hormone-induced cancers |
| | | | |
| | | | Vegeto Elisabetta
Macrophages and estrogen action: a positive interplay for inflammationrelated disorders |
| | | | |
| |
14:00 - 15:00
SIF-AIGO JOINT SYMPOSIUM - RECENT ADVANCES ON RIFAXIMIN PHARMACOLOGY AND THERAPEUTICS: MORE THAN JUST A SIMPLE ANTIBIOTIC | | | | | Gasbarrini Antonio
Microbial flora in health & disease and its modifications by systemic and poorly absorbed antibiotics |
| | | | |
| | | | Cianci Rossella
Innate and adaptive immunity of the human gut: effect of rifaximin |
| | | | |
| | | | Scarpignato Carmelo
Microbial flora and inflammation as therapeutic targets of rifaximin |
| | | | |
| |
15:00 - 16:00
SIF-SIC JOINT SYMPOSIUM - NEW PERSPECTIVES AND APPROACHES IN BACTERIAL INFECTIONS MANAGEMENT | | | | | Scaglione Francesco
Pharmacokinetics and pharmacodynamics of anti-Gram negative antibiotics |
| | | | |
| | | | Del Bono Valerio
Antimicrobial stewardship and infections due to MDR bacteria |
| | | | |
| | | | Mennini Francesco Saverio
The economic impact of bacterial infections management |
| | | | |
| |
16:00 - 18:00
SIF-SITOX JOINT SYMPOSIUM - THE HEALTH AND SOCIAL EFFECTS OF COUNTERFEIT DRUGS | | | | | Hrelia Patrizia
Potential health risk from counterfeit drugs |
| | | | |
| | | | Vecchio Sarah
Medicines online and health risks. Real case analysis |
| | | | |
| | | | Cantoni Orazio
Counterfeit medicines in developing countries |
| | | | |
| | | | Cesta Emanuele
Fighting counterfeiting: the role of AIFA |
| | | | |
| |
|
| | | | |
| | | | | SALA-A | 09:00 - 10:00
SIF-SIC JOINT SYMPOSIUM ANTI-GRAM POSITIVE ANTIBIOTICS FOR THE TREATMENT OF ABSSSI: EVOLUTION IS PHARMACOKINETICS! | | | | | Stefani Stefania
Epidemiology and resistance of Gram positive |
| | | | |
| | | | Scaglione Francesco
PK/PD of anti-Gram positive antibiotics |
| | | | |
| | | | Esposito Silvano
Advantages of the new anti-Gram positive antibiotics for the treatment of ABSSSI |
| | | | |
| |
14:00 - 15:45
ORAL COMMUNICATIONS - STEM CELLS IN CARDIOVASCULAR DISEASES | | | | | Torella D.
Cardiac stem cells are indispensable for heart homeostasis and repair |
| | | | |
| | | | Beltrami A. P.
Impact of heart failure on cardiac stem cells |
| | | | |
| | | | Urbanek K.
Cellular basis of drug induced heart failure: role of stem cells |
| | | | |
| | | | Sartiani L.
Modeling congenital heart defects with pluripotent stem cells: insights from human embryonic stem cells with trisomy 21 |
| | | | |
| | | | Gnecchi M.
Improving the therapeutic properties of mesenchymal stromal cells for ischemic heart disease |
| | | | |
| | | | Frati G.
Beta-blocker treatment in heart failure patients correlates with successful isolation of resident cardiac progenitor cells and affects their phenotype through EMT modulation |
| | | | |
| | | | Pompilio G.
Clinical trials in cardiovascular cell therapy: where we are going |
| | | | |
| |
16:00 - 16:30
EVOLUTION OF RESISTANCE: OLD AND NEW ANTIBIOTICS | | | | | Novelli Andrea
Introduction |
| | | | |
| | | | Concia Ercole
Evolution of resistance: old and new antibiotics |
| | | | |
| |
16:30 - 18:00
FOOD FOR THOUGHT: WHEN UNBALANCED DIETS LEAD TO UNBALANCED BRAINS | | | | | Banni Sebastiano
Role of dietary fat in modulating the biosynthesis of endocannabinoids and congeners in humans |
| | | | |
| | | | Fadda Paola
Vegetable shortening diet induced binge eating behavior: role of the endocannabinoid system |
| | | | |
| | | | Zamberletti Erica
Imbalances in dietary omega 3 intake from pregnancy impact adult offspring behavior through dysregulation of the endocannabinoid system |
| | | | |
| | | | Tucci Paolo
Pre and post-natal exposure to polyunsatured fatty acid enriched diet: impact on depression development in adult offspring |
| | | | |
| | | | Romano Adele
High dietary fat intake influences the central effects of the satiety factor oleoylethanolamide: possible implications for obesity management |
| | | | |
| |
|
| | | | |
| | | | | VESUVIO | 08:30 - 10:00
ALZHEIMER'S DISEASE: KEY PATHOGENETIC ISSUES FOR NOVEL THERAPEUTIC APPROACHES | | | | | Rowan Michael J.
Targeting synaptic plasticity disrupting Alzheimer's disease amyloid ß in vivo |
| | | | |
| | | | Cho Kei
Synapse weakening pathway: A new conceptual understanding of Alzheimer's disease |
| | | | |
| | | | Mancuso Cesare
The heme oxygenase/biliverdin reductase system in the brain of subjects with Down syndrome and later transition to Alzheimer's disease |
| | | | |
| |
14:00 - 15:00
DEPRESSION AND COGNITIVE SYMPTOMS: PHYSIOPATHOLOGICAL, CLINICAL AND PHARMACOTHERAPEUTIC ASPECTS - THIS EVENT WAS MADE POSSIBILE THANKS TO AN UNCONDITIONAL GRANT BY LUNDBECK | | | | | Grilli Mariagrazia
Pharmacological profile of vortioxetine: a novel and multimodal antidepressant drug |
| | | | |
| |
15:00 - 16:00
NEW HORIZONS IN IBD TREATMENT: THE ANTI-INTEGRIN THERAPIES - THANKS TO AN UNCONDITIONAL GRANT BY TAKEDA | | | | | Blandizzi Corrado
Gut selectivity: a new frontier in ibd treatment |
| | | | |
| | | | Daperno Marco
Role of anti-integrin drugs after conventional therapy failure: selective before systemic? |
| | | | |
| | | | Castiglione Fabiana
Tailoring the treatment: swapping or switching? Comparison of different therapeutic strategies |
| | | | |
| |
16:00 - 16:30
ROLE OF THE PDE4 INHIBITOR ROFLUMILAST IN THE MANAGEMENT OF SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE - THANKS TO AN UNCONDITIONAL GRANT BY TAKEDA | | | | | Geppetti Pierangelo
Introduction |
| | | | |
| | | | Fabbri Leonardo
Role of the PDE4 inhibitor roflumilast in the management of severe chronic obstructive pulmonary disease |
| | | | |
| |
16:30 - 17:30
SIF-AIGO JOINT SYMPOSIUM - UNIQUENESS OF BIOTECHNOLOGICAL DRUGS DEVELOPMENT AND PRODUCTION: REGULATORY, PHARMACOLOGICAL AND CLINICAL ASPECTS | | | | | Blandizzi Corrado
Biotechnological drugs development: from molecular and biological basis to the regulatory path |
| | | | |
| | | | Meroni Pier Luigi
Consistency of monoclonal antibodies: from production to clinical practice |
| | | | |
| |
|
| | | | |
| | | | | AUDITORIUM | 09:00 - 10:30
PHARMACOLOGY TEACHING | | | | | Amore Mario
National University Council (CUN) Activities |
| | | | |
| | | | Parolaro Daniela
Pharmacology Teaching in the School of Science |
| | | | |
| |
11:00 - 11:30
EMA PERSPECTIVES ON BIOSIMILARS | | |
|
| | | | |
| | | | | AULA-MAGNA | 08:30 - 10:15
ORAL COMMUNICATIONS - PHARMACOVIGILANCE - SESSION II | | | | | Sessa M.
Analysis of adverse drug reactions for preventability: a focus on psychotropic drugs |
| | | | |
| | | | Giannuzzi V.
Ethical issues and barriers for multi-national paediatric clinical trials: the challenging experience of the DEEP project |
| | | | |
| | | | Scavone C.
Atomoxetine in the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) and suicidal ideation (a case series) |
| | | | |
| | | | Lombardi N.
Children adverse drug reactions in Emergency Department: an analysis of MEREAFaPS study national database |
| | | | |
| | | | Carnovale C.
Throbbing headache associated with enoxaparin administration: a case report, a review of pharmacovigilance databases for similar cases and possible mechanisms |
| | | | |
| | | | Lapi F.
Concurrent use of low-dose aspirin and omega-3 fatty acids and risk of upper gastrointestinal complications: a cohort study with nested case-control analysis |
| | | | |
| | | | Auricchio F.
Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial) |
| | | | |
| |
11:00 - 12:30
ORAL COMMUNICATIONS - PSYCHOPHARMACOLOGY | | | | | Musazzi L.
Time-dependent structural, functional and behavioral changes induced by acute stress at excitatory synapses in prefrontal and frontal cortex. Implications for therapy of stress-related disorders |
| | | | |
| | | | Calabrese F.
Regulation of clock gene expression in the chronic mild stress model: modulatory activity of the novel drug lurasidone |
| | | | |
| | | | Guida F.
Intestinal microbiota perturbation induces depressive-like behavior associated with brain biochemical and functional alterations |
| | | | |
| | | | Lamberti M.
ECG parameters in children and adolescents treated with second generation antipsychotics: a 1-year prospective study |
| | | | |
| | | | Morgese M. G.
In utero exposure to omega-3 and omega-6 polyunsaturated fatty acid enriched diet: neurobiochemical and behavioral effects in the female rat offspring |
| | | | |
| | | | Mostallino M. C.
Effect of maternal care and chronic stress on neuronal plasticity in the rat hippocampus induced by maternal separation |
| | | | |
| |
|
| | | | |
| | | | | MIRABILIS-A | 08:30 - 10:30
ORAL COMMUNICATIONS - NEUROPHARMACOLOGY - SESSION II | | | | | Boccella S.
Palmitoylethanolamide chronic treatment reduces the sensorial and cognitive disfunctions associated with mild traumatic brain injury |
| | | | |
| | | | Piscitelli F.
Neuroprotective effects of N-oleoylglycine in a mouse model of mild traumatic brain injury |
| | | | |
| | | | Bonini S. A.
NF-?B p50 knock-out mice as animal model of autism |
| | | | |
| | | | Beggiato S.
Prenatal kynurenine treatment in mice: effects on placental and fetal brain kynurenines |
| | | | |
| | | | Leggio G. M.
Genetic-driven reduction of dopamine D3 receptor ameliorates dysbindin-dependent schizophrenia relevant abnormalities |
| | | | |
| | | | Formisano L.
Resveratrol via sirtuin-1 downregulates RE1-Silencing Transcription Factor (REST) expression preventing PCB-95-induced neuronal cell death |
| | | | |
| | | | Neri L.
Stimulation of brain melanocortin MC4 receptors enhances neurogenesis and counteract cognitive decline in a transgenic mouse model of Alzheimer's disease |
| | | | |
| | | | Ferraro L.
Differential effects of palmitoylethanolamide against amyloid-? induced toxicity in cortical neuronal and astrocytic primary cultures from wild-type and 3xTg-AD mice |
| | | | |
| |
11:00 - 12:30
RATIONAL USE OF ANTIBIOTICS IN PAEDIATRY | | | | | Clementi Emilio
Use and abuse of antibiotics for children |
| | | | |
| | | | Chiappini Elena
SIPPS Consensus for rational use of antibiotics in paediatry: a concrete example to modify Italian prescription habits |
| | | | |
| | | | Guarino Alfredo
Indication to antibiotics for respiratory tract infections in children |
| | | | |
| | | | De Martino Maurizio
EBM management of pneumonia in children |
| | | | |
| |
|
| | | | |
| | | | | MIRABILIS-B | 09:00 - 10:30
PREVENTION OF OPIOID DRUGS ABUSE | | | | | Mugelli, Romualdi
Introduction |
| | | | |
| | | | Gerra Gilberto
Risk of abuse and diversion of narcotic drugs: prevention measures |
| | | | |
| | | | Mannaioni Guido
Abuse, misuse, tolerance, dependence and addiction: the need of clear guidelines to avoid opiophobia |
| | | | |
| |
11:00 - 13:00
ORAL COMMUNICATIONS - PHARMACOLOGY OF ANTINEOPLASTIC DRUGS - SESSION II | | | | | Pagano E.
Monoacylglycerol lipase is crucially involved in experimental colon carcinogenesis |
| | | | |
| | | | Baiula M.
Resveratrol exerts anti-proliferative and pro-apoptotic effects through transcription factor REST in human medulloblastoma cells |
| | | | |
| | | | Bergamo A.
Seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A |
| | | | |
| | | | Muscari I.
Role of microRNAs in the activity of new therapeutic inhibitors of Src kinases in CD133+ colorectal cancer cells |
| | | | |
| | | | Lucarini L.
Carbonic anhydrase IX: target enzyme for diagnosis and therapy of renal cell carcinoma |
| | | | |
| | | | Serpe L.
Targeted gold nanoparticles as nanosonosensitizers in ultrasound based cancer treatment |
| | | | |
| | | | Tognolini M.
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin proteinprotein interaction |
| | | | |
| | | | Andreini I.
Preclinical safety assessment of cytotoxic and biotechnology anticancer drugs complying with the regulatory, scientific and ethical aspects? what a challenge! |
| | | | |
| |
|
| | | | |
| | | | | POSILLIPO | 08:30 - 10:00
OVERFEEDING, DYSMETABOLISM, INFLAMMATION AND STRESS EXPOSURE AS PROMINENT ACTORS IN THE DRAMA OF NEUROPSYCHIATRIC DISORDERS: NEW INSIGHTS FOR THE DEVELOPMENT OF NOVEL THERAPIES | | | | | Gaetani Silvana
Preclinical effects of oleoylethanolamide on normal food intake and on frustration stress-induced binge-like palatable food consumption: possible implications for eating disorders |
| | | | |
| | | | Passani Maria Beatrice
Key role of the brain histaminergic system at the crossroad of eating behaviour, weight gain and emotional memory: preclinical and clinical evidence |
| | | | |
| | | | Popoli Maurizio
Physical exercise- and stress-induced neuroplasticity changes in knock-in mice with the human BDNF Val66Met polymorphism |
| | | | |
| | | | Scuderi Caterina
Glial dysfunction in the pathogenesis of neuropsychiatric disorders: beyond inflammation, toward the development of novel therapies |
| | | | |
| | | | Steardo Luca
Discussion and concluding remarks |
| | | | |
| |
11:30 - 12:30
ASSEMBLY OF THE NATIONAL BOARD OF ACADEMIC PHARMACOLOGISTS | | |
|
| | | | |
| | | | | SALA-A | 08:30 - 10:30
ORAL COMMUNICATIONS - CARDIOVASCULAR PHARMACOLOGY - SESSION II | | | | | Rocca B.
In silico modelling of aspirin action on platelet and megakaryocyte cyclooxygenase-1 |
| | | | |
| | | | Petrucci G.
Pre-analytical biases in investigating low-dose aspirin responsiveness and comparison of two different methods |
| | | | |
| | | | Tarantino E.
Thromboxane pathway and venous thrombosis: ASA effects in mouse model |
| | | | |
| | | | Amadio P.
The display of pro-thrombotic phenotype of mice carrying the BDNF Val66Met human polymorphism is prevented by treatment with resveratrol |
| | | | |
| | | | Brambilla M.
Effect of captopril treatment on platelet tissue factor expression in stroke-prone rats |
| | | | |
| | | | Ciarambino T.
Sex gender and antithrombotic therapy in patients with atrial fibrillation: results from the ATA AF study by the Italian Scientific Societies ANMCO and FADOI |
| | | | |
| | | | Donnini S.
Prostaglandin E2 promotes the release of angiogenic factors from platelets: role of EP3 receptor |
| | | | |
| | | | Gelosa P.
PPAR alpha-agonist treatment prevents the development of cardiac hypertrophy in a rat model of renovascular hypertension |
| | | | |
| |
11:00 - 12:15
ORAL COMMUNICATIONS - PHARMACOLOGY OF METABOLISM ? SESSION II | | | | | Bitto A.
Effects of the antagomirs 15B and 200B in the altered healing pattern of diabetic wounds |
| | | | |
| | | | Chiazza F.
Protective effects of a PPAR-? agonist and a non-erythropoietic peptide derivative of erythropoietin against the diet-induced development of skeletal muscle insulin resistance and inflammation in mice |
| | | | |
| | | | Bellini G.
CB2 stimulation inhibits fat storage in lipid droplets and induces adipocyte browning |
| | | | |
| | | | Collino M.
Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice |
| | | | |
| | | | Ferraro E.
Improvement of skeletal muscle performance in aging by the metabolic modulator trimedazidine |
| | | | |
| |
|
| | | | |
| | | | | SALA-B | 08:30 - 10:30
ORAL COMMUNICATIONS - PHARMACOGNOSY | | | | | Turrini E.
Compounds of natural origin as promising inducers of immunogenic cell death |
| | | | |
| | | | Maione F.
Sedative-hypnotic like activity of 7-methyljuglone isolated from Diospyros lotus L. roots |
| | | | |
| | | | Smeriglio A.
Characterization of polyphenols and evaluation of antioxidant activity of finola hemp (Cannabis sativa L.) seed oil |
| | | | |
| | | | Romano B.
Antinflammatory effect of Cannabis extracts with high content in A9-tetrahydrocannabivarin (THCV) or cannabidivarin (CBDV) in murine macrophages |
| | | | |
| | | | Sangiovanni E.
Characterization and anti-inflammatory activity of Vitis vinifera L. leaves in human keratinocytes |
| | | | |
| | | | Rosseto A.
Anti-rheumatoid arthritis activity of decoction from the leaves of the tree Artocarpus tonkinensis used in Vietnamese traditional medicine |
| | | | |
| | | | Adorisio S.
Anti-cancer activity of compounds isolated from Bursera microphylla |
| | | | |
| | | | Testai L.
Naringenin confers cardioprotection against ischemia-reperfusion injury in aged rats |
| | | | |
| |
11:00 - 12:45
ORAL COMMUNICATIONS - INFLAMMATION PHARMACOLOGY AND IMMUNOPHARMACOLOGY - SESSION II | | | | | Impagnatiello F.
Intraocular pressure lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models of ocular hypertension and glaucoma |
| | | | |
| | | | Tirotta E.
Enteric bacteria alterations and inflammation associated with diclofenac-induced enteropathy: preventive effects of rifaximin |
| | | | |
| | | | Bettiol A.
Psoriasis: a hidden pathology |
| | | | |
| | | | Ianaro A.
ATB-346 a novel hydrogen sulfide-releasing anti-inflammatory drug induces apoptosis of human melanoma cells and inhibits melanoma development in vivo |
| | | | |
| | | | Fornai M.
Protective effects of rifaximin against experimental enteropathy induced by indomethacin in rat |
| | | | |
| | | | Veglia E.
H1 histamine receptor affects the integrity of glomerular slit diaphragm |
| | | | |
| | | | Iannotti F. A.
Study of the expression profile and pharmacological role of the CB1 receptor in Duchenne Muscular Dystrophy (DMD) muscles: a new opportunity to reinforce muscle repair and locomotor activity |
| | | | |
| |
|
| | | | |
| | | | | VESUVIO | 08:30 - 10:30
SIF-ITALIAN PURINE CLUB JOINT SYMPOSIUM - PURINERGIC ENZYMES: ROLE IN INFLAMMATORY/IMMUNE RESPONSES AND THERAPEUTIC IMPLICATIONS | | | | | Zuccarini Mariachiara
Modulation of the purinergic signaling by extracellular purine-converting enzymes under basal and mimicking pathophysiological conditions |
| | | | |
| | | | Tozzi Maria Grazia
Interaction between 5'-nucleotidase cN-II and the inflammasome protein NLRC4/Ipaf suggests new roles of cN-II in cell biology |
| | | | |
| | | | Antonioli Luca
Adenosine regulating agents as novel strategies for the pharmacological treatment of inflammatory bowel diseases |
| | | | |
| | | | Adinolfi Elena
Role of extracellular ATP and its receptor P2X7 in anti-tumoral immune response |
| | | | |
| | | | Cacciapuoti Giovanna
Archaeal purine nucleoside phosphorylase and gene therapy |
| | | | |
| |
11:00 - 12:45
ORAL COMMUNICATIONS - PHARMACOEPIDEMIOLOGY - SESSION II | | | | | Perrone V.
Use of oral anticoagulant therapy in the general population: a real-life study after new oral anticoagulants introduction |
| | | | |
| | | | Citarella A.
Choice of antithrombotic drug in non-valvular atrial fibrillation patients in real-world practice |
| | | | |
| | | | Sultana J.
Association of azithromycin and ventricular arrhythmia: the ARITMO project |
| | | | |
| | | | Roberto G.
Risk of acute cerebrovascular and cardiovascular events among users of paracetamol or paracetamol-codeine combination: a case-control study nested in a cohort of patients with osteoarthritis |
| | | | |
| | | | Piccinni C.
Exposure and clinical consequences of interactions with Non-Steroidal Anti Inflammatory Drugs in elderly poly-treated patients |
| | | | |
| | | | Cammarota S.
Healthcare costs associated with non-valvular atrial fibrillation: a population-based study |
| | | | |
| | | | Bolcato Jenny
Underuse of thromboprophylaxis in atrial fibrillation: populationbased cohort study |
| | | | |
| |
|
| | | | |
|
|